Illumina launches $100M consumer genomics venture; Benitec prices a tiny IPO;

@FierceBiotech: ICYMI: Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. Story | Follow @FierceBiotech

@JohnCFierce: No surprise, coming off a $70M crossover, RegenX Bio files $100M. S-1/Report | Follow @JohnCFierce

> Sequencing giant Illumina ($ILMN) recruited Warburg Pincus, the Mayo Clinic and Sutter Hill Ventures to launch Helix, a consumer genomics company setting sail with $100 million from its founders. More

> Benitec Biopharma ($BNTC) pulled off a downsized IPO, raising just $13.8 million after pricing 1.5 million shares at $9.21 each. The company is developing gene-silencing treatments for hepatitis, cancer and age-related macular degeneration. News

Medical Device News

@FierceMedDev: UPDATED with comment from Fujifilm: FDA slaps three duodenoscope manufacturers with warning letters. Article | Follow @FierceMedDev

@EmilyWFierce: San Diego's Genalyte reeled in $44M in a Series C round for its microchip testing platform. Release | Follow @EmilyWFierce

> WSJ: New devices for rectal cancer surgery reduce need for colostomies. Story

> Illumina, LabCorp, Mayo Clinic, Warburg assemble to back latest consumer genomics entrant: Helix. Article

> FDA slaps three duodenoscope manufacturers with warning letters over related devices. Report

harma News

@FiercePharma: ICYMI yesterday: Will docs jump on new biosims? Survey shows they'll need some nudging. More | Follow @FiercePharma

@EricPFierce: Xellia decides it's best to have U.S. sales operations next to Raleigh, NC, plant it's expanding. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Mylan hopes Disney can add new magic to its allergy-fighting kingdom. FiercePharmaMarketing story | Follow @CarlyHFierce

> Big Pharma, rejoice: China aims to speed up approvals for new meds. Story

> Merck's Keytruda ready for quick FDA action on big melanoma expansion. Report

> Boehringer trumpets Spiolto quality-of-life data as it looks for its niche in COPD. Article

Drug Delivery News

> BioDelivery snags new FDA approval for Onsolis after ditching Meda partnership. More

> Hydrogels: Study shows use in ulcerative colitis and Army invests in wound healing research. Report

> Checkmate Pharma gets $20M in Series A to develop cancer candidate with VLP platform. Story

> Cannabics Pharma's extended-release medical marijuana capsules available in Colorado. Item

> Intersect's steroid-releasing implant meets its endpoint in bid for expanded indication. Article

Pharma Manufacturing News

> FDA castigates three Mylan sterile drug plants in warning letter. News

> Hemispherx says plant upgrade will allow it to return its genital wart treatment to market. Item

> GSK resumes production at plant where Legionella bacteria was detected. Report

> Merck manufacturing shedding another 2,600 jobs. Story

> Novo Nordisk looks at building its first U.S. insulin plant. Article

Pharma Asia News

> More scrutiny for Japanese duodenoscope makers on notification failures. Report

> India's Lee Pharma turned down on CL challenge to AZ's Onglyza. Item

> Does China yuan devaluation mean more downbeat pharma earnings? Article

> Japan's Mitsui buys stake in India top drug wholesaler Keimed. Story

> Going private for WuXi PharmaTech opens dealmaking options. More

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.